Embed Size (px)
Citation preview
Tel +32 (0)2 221 81 81 • Fax +32 (0)2 221 81 74 • [email protected] • www.imi.europa.eu Postal address: IMI JU • TO56 • 1049 Brussels • Belgium • Visiting address: Ave de la Toison d’Or 56-60 • 1060 Brussels • Belgium
Webinar on IMI 2 – Call 20 topic Academia and industry united innovation and treatment for tuberculosis (UNITE4TB)
Participant list
23.01.2020
Name Surname Organisation Country e-mail address Potential contribution to the project in terms of expertise, resources and activities.
Narges Ahmidi HMGU Germany narges.ahmidi@gmai
l.com
AI, Causal Inference, Electronic Health Records, Early
Diagnosis of Diseases, Optimization of Treatment
Plans
Jose Ainsa University of
Zaragoza
Spain [email protected] We are partners in the IMI ERA4TB Consortium
where we are implementing the Hollow Fiber System
of Tuberculosis in a BSL3.
tonino alonzi INMI L.
Spallanzani
IRCCS
Italy [email protected] Molecular Biology, patients samples, networking
Meritxell Ascanio BCN Health
Economics &
Outcomes
Research S.L.
Spain meritxell.ascanio@bc
nhealth.com
Design and conduct cost-effectiveness analysis,
economic evaluations of observational/retrospecticve
data sets, medical writing
Joanna Bacon public Health
England
United Kingdom [email protected]
ov.uk
Tuberculosis, Drug Discovery
Sarra BEN ATTIA Luxembourg
Institute of
Health
Luxembourg [email protected] NA
Name Surname Organisation Country e-mail address Potential contribution to the project in terms of expertise, resources and activities.
Charles Betz Luxinnovation Luxembourg charles.betz@luxinno
vation.lu
Link to Luxembourgish health system and research
ecosystem
Janneke Boere Lygature Netherlands janneke.boere@lygat
ure.org
Project management, communications, patient
engagement, data management
Martin Boeree Radboudumc Netherlands martin.boeree@radb
oudumc.nl
Clinical trials experience
Alberto M. Borobia La Paz University
Hospital
(SERMAS)
Spain alberto.borobia@sal
ud.madrid.org
Experts in design, development and management of
Clinical Trials. Leaders of WP7 and WP9 ERA4TB
(Phase 1/FTIH trials and Ethics)
Willo Brock TB Alliance United States willo.brock@tballianc
e.org
Proven expertise in managing and running TB clinical
trials (incl phase 2/3) and regulatory approval for TB
drugs at FDA and EMA
Marieke Bruinsma Mimetas Netherlands m.bruinsma@mimet
as.com
High throughput microfluidic 3D cell/tissue culture
models
Martha Brumfield Critical Path
Institute
United States mbrumfield@c-
path.org
Regulatory science and novel methodology, data
management
Jonathan Butcher BioVersys Switzerland Jonathan.j.butcher@
bioversys.com
BioVersys has experience in anti-TB drug R&D,
including own projects, incl. basic target research,
MedChen and development.
Mariana Buziashvili National Center
for Tuberculosis
and Lung
Diseases
Georgia buziashvili.mari@gm
ail.com
I have an experience of working on many key
projects concerning TB in Georgia and I think I can
be of a great value to the team
Name Surname Organisation Country e-mail address Potential contribution to the project in terms of expertise, resources and activities.
ANDREA CALCAGNO University of
Torino
Italy andrea.calcagno@un
ito.it
Clinical Pharmacology, Trials conduction
Filippo Castiglione National
Research Council
of Italy
Italy filippo.castiglione@c
nr.it
Modeling and simulation of biological systems,
immunology, data analysis, bioinformatics
Corentin Chaboud BIOASTER France corentin.chaboud@b
ioaster.org
host biomarkers studies, host blood RNA-Seq
signatures , ERA4TB Task Leader
Francis P. Crawley GCPA & SIDCER Belgium [email protected] Member, IMI Pool of Patient Experts. Ethics Advisor
and/or Data Protection Officer on IMI(1&2) and
European Commission Projects
Zeger De Groote CMAST/MODIS Belgium zeger.de.groote@mo
disbelgium.be
Project management/writing Consultancy
remco de vrueh
Netherlands remco.devrueh@lyga
ture.org
Project/Partnership management
Claudia Denkinger University of
Heidelberg
Germany claudia.denkinger@u
ni-heidelberg.de
TB diagnostics, trial experience, modelling, decision
frameworks on advancement
Mara Diaconu Norwegian
University of
Science and
Technology,
Faculty of
Medicine and
Health Sciences
Norway mara.diaconu@ntnu.
no
Expertise in IMI, leading research in field, clinical
trials, HUNT study data and other data set
Name Surname Organisation Country e-mail address Potential contribution to the project in terms of expertise, resources and activities.
Antonia Diukendjieva Institute for
Medical
Research
Bulgaria antonia.diukendjieva
@imresearch.co
Clinical Trial Services, Validation Studies, Medical
Writing and Editing
ANNA DZIUBCZYNSKA-
PYTKO
IPPT PAN KPK PB
UE
Poland [email protected]
.pl
I'm IMI NCP
Lanfranco Fattorini Istituto Superiore
di sanità
Italy lanfranco.fattorini@is
s.it
Drug activity against MDR/XDR and dormant Mtb
(hypoxic (Wayne) model at pH 5.8 and 7.3, to mimic
macrophages and caseum)
Wolfgang Fecke EU-
OPENSCREEN
ERIC
Germany wolfgang.fecke@eu-
openscreen.eu
Access to compound libraries and assay
development capabilities, access to infectious
disease-focused partner institutes
Trude Helen Flo Norwegian
University of
Science and
Technology
Norway [email protected] Host-pathogen; BSL3 imaging; 3D EM; innate
immunity; trafficking; cell death; human primary cells;
iPSCs; cell lines; signalling
Marcus Furch Rodos Biotarget
GmbH
Germany m.furch@biotargetin
g.eu
therapeutic assets in preclinical development
Sandeep Ghorpade H3D, University
of Cape Town
South Africa sandeep.ghorpade@
uct.ac.za
Industrial experience in malaria and TB drug
discovery, lead optimisation and preclinical drug
development
SUDIP GHOSH TATA
CUMMINS LTD
AMS
India kanan_2022@rediffm
ail.com
DR.SUMIT GHOSH M.D. CMRI HOSPITAL
KOLKATTA
Name Surname Organisation Country e-mail address Potential contribution to the project in terms of expertise, resources and activities.
Federico Giannoni Istituto Superiore
di Sanità
Italy federico.giannoni@is
s.it
Our group has a long experience in many fields of M.
tuberculosis research, mainly drug testing in vitro and
molecular biology
Marta GOMEZ
QUINTANILLA
CDTI Spain [email protected]
s
My experience in IMI.
AFRICA GONZÁLEZ
FERNÁNDEZ
UNIVERSITY OF
VIGO
Spain [email protected] Basic and Applied Immunology. Studies with very
well controlled TB patients and contacts (LTBI-No-
TBI) from Galician TB Units.
CONCEPCIÓN GONZÁLEZ-
BELLO
Universidade de
Santiago de
Compostela,
CIQUS
Spain concepcion.gonzalez
small organic molecules synthesis targetting selected
targets, simulation studies, protein X-ray
crystallography, inhibitors
cyril guyard BIOASTER France cyril.guyard@bioaste
r.org
PI on ERA4TB biomarkers WP, Molecular signatures
discovery and validation, Industry standards
Hossam Haick Technion - IIT Israel hhossam@technion.
ac.il
Advanced sensors and wearable devices for
diagnosis and monitoring of treatment
Matthias Heinig Helmholtz
Zentrum Munich
Germany matthias.heinig@hel
mholtz-muenchen.de
Computational biology, machine learning
Leonard Herbst TCD Global South Africa leonard.herbst@tcd-
global.com
TCD is a local CRO based in South Africa, specialising
in the Regulatory, Project Management, Monitoring
and Site management.
Ellen Hubin Modis Belgium ellen.hubin@modisb
elgium.be
Project Management/Writing Consultancy
Alba Jene Sanz BSC Spain [email protected] Technical management
Name Surname Organisation Country e-mail address Potential contribution to the project in terms of expertise, resources and activities.
claus stie Kallesøe grit42 Denmark [email protected] Participated in several IMI projects. We deliver our
data storage platform used in ND4BB, AMR
COMBINE, AMR GNANOW etc
Eanna Kiely ClinBuild Germany eanna.kiely@clinbuil
d.com
CDISC standards author/trainer/consultant work with
academics. Standards are a core HMA/EMA Big Data
and H2020 recommendation.
Eka Kokhreidze National Center
for Tuberculosis
and Lung
Disease
Georgia ekokhreidze@yahoo.
com
I am public health manager and a researcher and I
work in a few projects as a coordinator, PI, ect.
Wim-Jan Koot Stichting
Lygature
Netherlands wim-
g
Programme Management, Regulatory Innovarion,
Data infrastructure, Patient Engagement, project
infrastructure
Gergana Kyosovska Bulgarian
Association for
Personalized
Medicine
Bulgaria gergana.kyosovska@
pdc-eu.com
Consultation and expert services in the field of
personalized medicine and public health
Christoph Lange Research Center
Borstel, Leibniz
Lung Center
Germany [email protected] Coordinating experience in clinical TB research in
Europe for greater 15 years; Director of a TB research
institute
Richard Liwski Critical Path
Institute
United States [email protected] skills and experience in: TB Data Management,
Translational Research, Modelling and simulation,
Regulatory science
Name Surname Organisation Country e-mail address Potential contribution to the project in terms of expertise, resources and activities.
Letícia Lobo Fondation
Mérieux
France leticia.lobo-
luppi@fondation-
merieux.org
expertise en multicenter studies on latent and active
TB in high burden countries
Anu Mahalingashetty TB Alliance United States anu.shetty@tballianc
e.org
Clinical trial execution
Anandi Martin Université
catholique de
Louvain (UCL)
Belgium Anandi.Martin@uclo
uvain.be
Innovation for TB treatment, drug resistance
mechanism, diagnosis developement
Eugenia Meiler CEMIR, NTNU Norway eugenia.meiler@ntn
u.no
Drug discovery in virulence and HDT against TB, in
vitro models of infection based on PBMC and iPSC-
Macs, cell death, imaging
Michael Menden Helmholtz
Zentrum Munich
Germany michael.menden@he
lmholtz-
muenchen.de
Bioinformatics and Biostatistics Analysis
Joana Mendes UNITE Portugal joana.mendes@unite
network.org
Engage with members of parliament, calling for
leadership to change laws and adequate budget
allocation to end IDs
JOSE LUIS NARRO
VILLANUEVA
FUNDACIÓN
PARA LA
INVESTIGACIÓN
BIOMÉDICA
HULP
Spain jose.luis.narro@idipa
z.es
Experience in H2020 and IMI project as a partner. My
role is Project Manager
vahid nouri Kandany PUCAM Dominican Republic [email protected] no
Name Surname Organisation Country e-mail address Potential contribution to the project in terms of expertise, resources and activities.
Lars Oetjen Nisooh Inc. United States lars.oetjen@nisooh11.
com
Support of Associated Partner (BMGF) to the
program
Patrick O'Meara Critical Path
Institute, Ltd.
Ireland [email protected] Data Management planning and oversight
Ralf Otto-Knapp DZK Germany rotto-knapp@dzk-
tuberkulose.de
Co-authorship of German TB guideline, committee of
national TB experts, one of the largest German out-
and in-patients TB clinic
Nick Paton NUS Singapore [email protected]
u.sg
Experience with TB trial design and all aspects of
conduct of phase 2a and 2b TB trials, TB clinical trial
site network
CECILE PELTEKIAN
cecile.peltekian@pas
teur.fr
Attending to the webinar to have an overview of the
call. Our Institute has expertise in TB Research
Michel Pieren
michel.pieren@biove
rsys.com
Expertise in clinical development of TB drugs
Sandra Pla SYNAPSE
Research
Management
Partners S.L
Spain spla@synapse-
managers.com
Project Management
Javier Pomar ARAID Spain [email protected] Umbrella organisation, network of researchers in the
region of Aragon.
Santiago Ramon Garcia ARAID
Foundation/Univ
ersity of
Zaragoza
Spain [email protected]
s
We are partners in the IMI ERA4TB Consortium in
which we are implementing the Hollow Fiber System
of Tuberculosis in BSL3.
Name Surname Organisation Country e-mail address Potential contribution to the project in terms of expertise, resources and activities.
Peggy Reich IMMS gGmbH Germany Peggy.Reich@imms.
de
Expertise in Microelectronics especially ASICs,
miniaturization of measurement devices, device
development for diagnostics
Santi RELLO-VARONA IdiPAZ Spain international.projects
@idipaz.es
IdiPAZ is the research institute of the flagship tertiary
hospital in Madrid. We have key expertise in clinical
trials.
Rofagha Rofagha Schuttelaar &
Partners
Belgium [email protected]
et
Societal impact studies, communication expertise
(incl. strategy, website, videos, events, social media),
project management
Andrea Roig Alba Radboudumc Netherlands andrea.roigalba@rad
boudumc.nl
Grant Support Office - Radboudumc
Romana Ruiss ARTTIC SAS Germany [email protected] Expertise in proposal development, project and
financial management, progress controlling
Chen Sagiv
chen@deepathology.
ai
TB detection in pathology images
Sònia Sagristà IDIBELL Spain [email protected] Clinical & basic reserach skills on tuberculosis
Gunnar Sandberg VInnova Sweden gunnar.sandberg@vi
nnova.se
SRG
Peter Sander University of
Zurich, National
Laboratory for
Mycobacteria
Switzerland [email protected]
h
Screening facilities, experience in Screening, BSL3, TB
strain collection
isabelle saves CNRS France [email protected]
r
fundamental academic research on TB
Name Surname Organisation Country e-mail address Potential contribution to the project in terms of expertise, resources and activities.
Fraser Scott
United Kingdom fraser.j.scott@strath.
ac.uk
Novel drug class
nir shaled ISERD Israel [email protected] Israeli potential consortia partners from Academy
and Industry
zvia shwirtz TB Alliance United States zvia.shwirtz@tballian
ce.org
Proposal submission
Dan Sivilli Critical Path
Institute
United States [email protected] We are participating in the ERA4TB Consortia
(European Regimen Accelerator for TB)
Jan Skriwanek National Contact
Point Health
Germany [email protected] NCPs provide consultancy & support for researchers
applying for IMI topics
Montserrat Sole Institut
Biotecnologia i
Biomedicina (IBB)
montserrat.sole.caste
Biosensors for detecting Tuberculosis
Magnus Steigedal NTNU Norway [email protected] Molekylær biologi om mtb. Host-pathogen
interactions
Thavirap Tantiwongse The
Pharmaceutical
Research and
Manufacturers
Association
Thailand [email protected]
h
Clinical Trials Network, Thai Healthcare Professionals
Network, Governmental and Academic Collaborators
Sanchia Theron Triclinium Clinical
Development
South Africa sanchia.theron@tcd-
global.com
TCD is a SA-based CRO offering end-to-end clinical
development services with vast experience in the
field of infectious disease.
Name Surname Organisation Country e-mail address Potential contribution to the project in terms of expertise, resources and activities.
Guy Thwaites University of
Oxford
Viet Nam [email protected]
g
Clinical trial expertise
Caroline Toex DLR-PT Germany [email protected] Health NCP
Dagmar Vaclavikova Masaryk
University
Czech Republic dagmar.vaclavikova
@med.muni.cz
Team working with TB patients
Abraham van Wyk Triclinium Clinical
Development
South Africa abraham.vanwyk@tc
d-global.com
We are an African focussed CRO, specialising in ID,
with special interest in TB and vaccines.
Juan Jose Vaquero Universidad
Carlos III de
Madrid
Spain juanjose.vaquero@u
c3m.es
Previous experience on TB related projects: Imaging
technologies, data analysis, engineering resources.
David Verde IDIOAPJGOL Spain [email protected]
o
Primary Care
Alessandra Veronese Accademia dei
Pazienti
Italy [email protected]
om
I can bring my expertise either as Expert Patient
EUPATI Italy, or as Clinical Research Expert with 20
years of experience
Rotem Vishinkin Technion - Israel
Institute of
Technology
Israel rvishinkin@technion.
ac.il
An expertise in developing noval non-invasive TB
diagnostics, vast activities with the industry and
organizations, such as BMGF.
Ursula Wirtz ConsulTech
GmbH
Germany [email protected] support in the administrative grant process, proposal
writing, grant- and projectmanagement, online
collaboration plattform
Emre YARCI Association of
Research-Based
Pharmaceutical
Turkey [email protected]
r
Network facilitation
Name Surname Organisation Country e-mail address Potential contribution to the project in terms of expertise, resources and activities.
Companies
(AIFD)
İlker Yeşilkaya DNB ( Decision &
Behavior)
Analytics LLC.
Turkey ilkeryesilkaya@dnba
nalytics.com
AI- based clinical behavioral research platform
focused on psychiatric disorders
İlker Yeşilkaya DNB (Decision &
Behaviour)
Analytics LLC
Turkey ilkeryesilkaya@dnba
nalytics.com
DNB (Decision & Behavior) Analytics LLC.
